Evidence map›Paper›PMID 26912061›Full record

ArticleTumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine2016

Recurrent CDK1 overexpression in laryngeal squamous cell carcinoma.

K Bednarek, K Kiwerska, M Szaumkessel, M Bodnar, M Kostrzewska-Poczekaj, A Marszalek, J Janiszewska, A Bartochowska, J Jackowska, M Wierzbicka and 4 more

Open access · hybridAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers.

0numbers the graph read from it
0cells of the map it votes in
25citing papers in PubMed
2.3field-weighted citation impact, top 12% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

25 citing papers in PubMed, 64 citations in OpenAlex.

  1. Article
  2. Combining serum CDK1 with tumor markers for the diagnosis of small cell lung cancer.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2025
    Article
  3. Article
  4. Article
  5. Review
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors at 5 institutions in 2 countries.

K BednarekDepartment of Cancer Genetics, Institute of Human Genetics, PAS, Poznan, Poland.
K KiwerskaDepartment of Cancer Genetics, Institute of Human Genetics, PAS, Poznan, Poland.
M SzaumkesselDepartment of Cancer Genetics, Institute of Human Genetics, PAS, Poznan, Poland.
M BodnarDepartment of Clinical Pathomorphology, Collegium Medicum, Nicolaus Copernicus University, Bydgoszcz, Poland.
M Kostrzewska-PoczekajDepartment of Cancer Genetics, Institute of Human Genetics, PAS, Poznan, Poland.
A MarszalekDepartment of Clinical Pathomorphology, Collegium Medicum, Nicolaus Copernicus University, Bydgoszcz, Poland.
J JaniszewskaDepartment of Cancer Genetics, Institute of Human Genetics, PAS, Poznan, Poland.
A BartochowskaDepartment of Otolaryngology and Laryngological Oncology, University of Medical Sciences, Poznan, Poland.
J JackowskaDepartment of Otolaryngology and Laryngological Oncology, University of Medical Sciences, Poznan, Poland.
M WierzbickaDepartment of Otolaryngology and Laryngological Oncology, University of Medical Sciences, Poznan, Poland.
R GrenmanDepartment of Otorhinolaryngology-Head and Neck Surgery and Department of Medical Biochemistry, Turku University Hospital and University of Turku, Turku, Finland.
K SzyfterDepartment of Audiology and Phoniatry, University of Medical Sciences, Poznan, Poland.
M GiefingDepartment of Cancer Genetics, Institute of Human Genetics, PAS, Poznan, Poland.
M Jarmuz-SzymczakDepartment of Cancer Genetics, Institute of Human Genetics, PAS, Poznan, Poland. maljar@man.poznan.pl.
Institute of Human Genetics · PLPoznan University of Medical Sciences · PLGreater Poland Cancer Center · PLNicolaus Copernicus University · PLTurku University Hospital · FI

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

In this study, we analyzed the expression profile of four genes (CCNA2, CCNB1, CCNB2, and CDK1) in laryngeal squamous cell carcinoma (LSCC) cell lines and tumor samples. With the application of microarray platform, we have shown the overexpression of these genes in all analyzed LSCC samples in comparison to non-cancer controls from head and neck region. We have selected CDK1 for further analysis, due to its leading role in cell cycle regulation. It is a member of the Ser/Thr protein kinase family of proven oncogenic properties. The results obtained for CDK1 were further confirmed with the application of reverse transcription quantitative polymerase chain reaction (RT-qPCR) technique, Western blot, and immunohistochemistry (IHC). The observed upregulation of CDK1 in laryngeal squamous cell carcinoma has encouraged us to analyze for genetic mechanisms that can be responsible this phenomenon. Therefore, with the application of array-CGH, sequencing analysis and two methods for epigenetic regulation analysis (DNA methylation and miRNA expression), we tried to identify such potential mechanisms. Our attempts to identify the molecular mechanisms responsible for observed changes failed as we did not observe significant alterations neither in the DNA sequence nor in the gene copy number that could underline CDK1 upregulation. Similarly, the pyrosequencing and miRNA expression analyses did not reveal any differences in methylation level and miRNA expression, respectively; thus, these mechanisms probably do not contribute to elevation of CDK1 expression in LSCC. However, our results suggest that alteration of CDK1 expression on both mRNA and protein level probably appears on the very early step of carcinogenesis.

Indexed as

AdultAgedAged, 80 and overBiomarkers, TumorBlotting, WesternCarcinoma, Squamous CellCDC2 Protein KinaseCell Line, TumorCyclin-Dependent KinasesFemaleHead and Neck NeoplasmsHumansImmunohistochemistryLaryngeal NeoplasmsMaleMiddle AgedBiomarkers, TumorCDC2 Protein KinaseCDK1 protein, humanCyclin-Dependent KinasesCDK1Gene methylationImmunohistochemistrymicroRNAOverexpressionWestern blot

Identifiers

PMID26912061
PMCPMC4999469
OpenAlexW2284480180

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.